Market Overview

Athersys Granted New Patents in Japan for Stem Cell, Regenerative Medicine Technology

Athersys (Nasdaq: ATHX) today announced that it has been granted patents from the Japan Patent Office for several inventions involving its proprietary cell therapy technology. Patent No. 5398941 covers non-embryonic, multipotent stem cells, such as MultiStem, and applies to all therapeutic applications. Patent No. 5399709 covers the use of such stem cell therapies for the treatment of immune dysfunctions, such as graft-versus-host disease (GvHD), and inflammatory diseases and autoimmune disorders (e.g., inflammatory bowel disease (IBD)). And, the third patent covers the treatment of brain injuries, such as stroke and traumatic brain injury, with such multipotent stem cells. 

See full press release

Posted-In: News Guidance Management Global

 

Most Popular

Related Articles (ATHX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free